U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H38O3
Molecular Weight 374.5567
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 5
Charge 0

SHOW SMILES / InChI
Structure of ICOSABUTATE

SMILES

CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O

InChI

InChIKey=VOGXDRFFBBLZBT-AAQCHOMXSA-N
InChI=1S/C24H38O3/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-27-23(4-2)24(25)26/h5-6,8-9,11-12,14-15,17-18,23H,3-4,7,10,13,16,19-22H2,1-2H3,(H,25,26)/b6-5-,9-8-,12-11-,15-14-,18-17-

HIDE SMILES / InChI

Molecular Formula C24H38O3
Molecular Weight 374.5567
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 5
Optical Activity ( + / - )

Icosabutate (also known as PRC-4016 or NST-4016), a cholesterol ester transfer protein inhibitor was developed by NorthSea Therapeutics for the treatment of combined dyslipidemias and hypertriglyceridemia. Icosabutate successfully completed phase II clinical trial for hypertriglyceridemic subjects, where was studied the drug efficacy and safety. In April 2018 NorthSea Therapeutics announced that its lead product, icosabutate would be further developed as an effective and safe therapeutic approach to treating both non-alcoholic steatohepatitis and its associated comorbidities.

Approval Year

PubMed

PubMed

TitleDatePubMed
Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
2016 Jan-Feb
Patents

Sample Use Guides

After a 6-8 week run-in period, men and women with TG levels ≥ 500 mg/dL and ≤ 1500 mg/dL were randomized to double-blind treatment with placebo or icosabutate 600 mg for 12 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:30:21 GMT 2023
Edited
by admin
on Sat Dec 16 09:30:21 GMT 2023
Record UNII
562599X5JL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ICOSABUTATE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
PRB-01022
Code English
Icosabutate [WHO-DD]
Common Name English
BUTANOIC ACID, 2-((5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-EICOSAPENTAEN-1-YLOXY)-
Systematic Name English
NST-4016
Code English
rac-2-[(5Z,8Z,11Z,14Z,17Z)Icosa-5,8,11,14,17-pentaen-1-yloxy]butanoic acid
Systematic Name English
ICOSABUTATE [USAN]
Common Name English
icosabutate [INN]
Common Name English
PRC-4016
Code English
Code System Code Type Description
DRUG BANK
DB12990
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
USAN
CD-89
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
NCI_THESAURUS
C166820
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
FDA UNII
562599X5JL
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL3707220
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
INN
9888
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
PUBCHEM
78210211
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
SMS_ID
100000180107
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
CAS
1253909-57-7
Created by admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
PARENT -> DERIVATIVE
Related Record Type Details
ACTIVE MOIETY